U.S. Markets closed
  • S&P 500

    4,536.19
    +16.56 (+0.37%)
     
  • Dow 30

    35,609.34
    +152.03 (+0.43%)
     
  • Nasdaq

    15,121.68
    -7.41 (-0.05%)
     
  • Russell 2000

    2,289.77
    +13.85 (+0.61%)
     
  • Gold

    1,782.90
    +12.40 (+0.70%)
     
  • EUR/USD

    1.1659
    +0.0022 (+0.1865%)
     
  • 10-Yr Bond

    1.6360
    +0.0010 (+0.06%)
     
  • Vix

    15.49
    -0.21 (-1.34%)
     
  • GBP/USD

    1.3820
    +0.0026 (+0.1921%)
     
  • USD/JPY

    114.2410
    -0.1190 (-0.1041%)
     
  • BTC-USD

    65,877.33
    +1,911.29 (+2.99%)
     
  • CMC Crypto 200

    1,538.50
    +57.70 (+3.90%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So should Capricor Therapeutics (NASDAQ:CAPR) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

See our latest analysis for Capricor Therapeutics

Does Capricor Therapeutics Have A Long Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at June 2021, Capricor Therapeutics had cash of US$38m and no debt. Importantly, its cash burn was US$15m over the trailing twelve months. So it had a cash runway of about 2.5 years from June 2021. Arguably, that's a prudent and sensible length of runway to have. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Capricor Therapeutics' Cash Burn Changing Over Time?

Whilst it's great to see that Capricor Therapeutics has already begun generating revenue from operations, last year it only produced US$320k, so we don't think it is generating significant revenue, at this point. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. The skyrocketing cash burn up 128% year on year certainly tests our nerves. It's fair to say that sort of rate of increase cannot be maintained for very long, without putting pressure on the balance sheet. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Capricor Therapeutics To Raise More Cash For Growth?

While Capricor Therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Capricor Therapeutics' cash burn of US$15m is about 17% of its US$90m market capitalisation. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is Capricor Therapeutics' Cash Burn Situation?

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Capricor Therapeutics' cash runway was relatively promising. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about Capricor Therapeutics' situation. On another note, Capricor Therapeutics has 4 warning signs (and 1 which can't be ignored) we think you should know about.

Of course Capricor Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.